JUSTICE研究:Baricitinib治疗APOL1相关肾病二期试验设计
JUSTICE是一项单中心、随机、双盲、安慰剂对照的二期先导试验,计划纳入75例非糖尿病APOL1相关FSGS或HTN-CKD患者,按2:1随机接受baricitinib或安慰剂治疗,主要评估6个月尿白蛋白肌酐比变化及血红蛋白下降的安全性。
要点
- APOL1 G1/G2变异经JAK-STAT信号上调表达,驱动FSGS和高血压相关终末期肾病。
- Baricitinib为口服JAK1/2抑制剂,可阻断APOL1合成,该试验评估其降低蛋白尿的疗效与安全性。
- 主要疗效终点为6个月UACR较基线百分比变化,主要安全终点为血红蛋白显著下降≥1g/dl的发生率。
核心结论
- JUSTICE二期试验将描述baricitinib在APOL1相关FSGS和HTN-CKD患者中的降蛋白尿疗效与安全性。
研究设计与样本
- JUSTICE为单中心、随机、双盲、安慰剂对照的二期先导试验。
- 计划纳入75例非洲裔美国APOL1相关CKD患者,其中FSGS 25例、HTN-CKD 50例,年龄18至70岁,无糖尿病。
- 患者按2:1随机接受每日baricitinib或安慰剂治疗。
关键数值与推荐
- 主要疗效终点为基线至第6个月末尿白蛋白肌酐比(UACR)的百分比变化。
- 主要安全终点为血红蛋白临床显著下降≥1g/dl的发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Individuals of recent West African ancestry develop focal segmental glomerulosclerosis (FSGS) and hypertension-attributed end-stage kidney disease (HTN-ESKD) at 4 times the rate of White Americans. Two protein-coding variants of the Apolipoprotein L1 (APOL1) gene, G1 and G2, explain 50% to 70% of the excess risk of HTN-ESKD and FSGS among this group. Increased expression of G1 and G2 in the kidney, mediated by Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling, drive pathogenesis of these kidney diseases. Baricitinib is an orally active inhibitor of JAK1/2 that blocks APOL1 synthesis. The Janus kinase-STAT Inhibition to Reduce APOL1-Associated Kidney Disease (JUSTICE) trial is evaluating the antiproteinuric efficacy and safety of baricitinib in patients with APOL1-associated FSGS and HTN-attributed chronic kidney disease (HTN-CKD). METHODS: JUSTICE is a single-center, randomized, double-blind, placebo-controlled, pilot phase 2 trial of baricitinib in patients with proteinuria, APOL1-associated FSGS or APOL1-associated HTN-CKD without diabetes. A total of 75 African American patients with APOL1-associated CKD, including 25 with FSGS and 50 with HTN-CKD, aged 18 to 70 years will be randomized 2:1 to daily treatment with baricitinib or placebo, respectively. RESULTS: The primary efficacy end point will be percent change in urine albumin-to-creatinine ratio (UACR) from baseline to end of month 6. The primary safety end point will be incidence of clinically significant decreases in hemoglobin of ≥ 1g/dl. CONCLUSION: The phase 2 JUSTICE study will characterize the antiproteinuric efficacy and safety of JAK1/2 inhibition with baricitinib in patients with APOL1-associated FSGS and APOL1-associated HTN-CKD.
引用
- Olabisi OA, Barrett NJ, Lucas A, et al. Design and Rationale of the Phase 2 Baricitinib Study in Apolipoprotein L1-Mediated Kidney Disease (JUSTICE). Kidney Int Rep. 2024. PMID: 39291185. doi:10.1016/j.ekir.2024.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。